An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants

NCT02273882 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 497

Last updated 2017-05-23

No results posted yet for this study

Summary

Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.

Conditions

  • Respiratory Syncytial Virus Hospitalizations

Sponsors & Collaborators

Principal Investigators

  • Christopher Ambrose, MD · AstraZeneca

  • Veena Kumar, MD, MPH · AstraZeneca

Eligibility

Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-17
Primary Completion
2016-08-19
Completion
2016-08-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273882 on ClinicalTrials.gov